Abstract
Although current screening with flexible sigmoidoscopy and fetal occult blood test likely reduce colon cancer mortality, it is costly and probably not as effective as one-time screening with colonoscopy for detecting and preventing cancer, as well as risk stratification for further testing and surveillance. Ideal screening would target sensitive tests at high-risk individuals. It is possible that the identification of genetic or biologic markers in the future will enable us to target screening at high-risk individuals with precision.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 501-511 |
| Number of pages | 11 |
| Journal | Primary Care - Clinics in Office Practice |
| Volume | 22 |
| Issue number | 3 |
| State | Published - 1995 |
ASJC Scopus subject areas
- Pharmacology (medical)